PETACH TIKVA, Israel, November 28, 2016 /PRNewswire/ --
The goal of HITS is to find start up technology companies from around the world that are early in their evolution which Merck can partner with and/or co-create services that complement their core products and future pipeline. After reviewing more than 400 worldwide startup companies in the information technology industry this year, Emerald was selected as one of eight companies to participate in the final judging, which took place on Nov 10, 2016.
Emerald's CEO and President, Adi Zamir and Lior Wayn, presented to Merck's senior executives at the HITS "Be Well Challenge" final, where they were named one of the four winners. As one of the selected winners, Merck has committed to a due diligence process that will determine the potential feasibility of a partnership with the Company.
Adi Zamir CEO of Emerald said "We are proud to have our technology chosen as a winner by a company of Merck's caliber. Their dedication to patients with melanoma is clear; Keytruda is the leading immunotherapy product for melanoma in the world. We believe DermaCompare's ability to identify moles that are suspicious of melanoma could add value to Merck's efforts in the treatment of skin cancer, and look forward to working with them to figure out the best way to implement our technology so that they may help many more people worldwide."
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical technology company that utilizes proprietary military image processing technology and state of the art data analytics to improve the analysis of medical images. Emerald's flagship solution, DermaCompare™, is an FDA Class #1 approved, HIPPA-compliant, skin cancer (melanoma) screening platform that enables physicians to identify and monitor changes in their patients' skin health, specifically the early detection of cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in Mac or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography ("TBP") images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficient than other means of diagnosis
For more information, visit :http://www.dermacompare.com/
About Merck & Co. Inc.
Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through its prescription medicines, vaccines, biologic therapies and animal health products, Merck works with customers and operates in more than 140 countries to deliver innovative health solutions. The company also demonstrates its commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit http://www.merck.com, Twitter, Facebook, YouTube and LinkedIn.
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about Emerald's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Emerald or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Emerald with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Emerald's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Emerald's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Emerald's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Emerald's filings with the SEC. In addition, Emerald operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Emerald does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission on January 20, 2016.
Emerald Medical Applications Contact: Adi Zamir, CEO +972-54-4861247 +972-3-7444505 [email protected]
SOURCE Emerald Medical Applications Corp.
Advertisement
Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or the "Company"), the Israeli-based company engaged in the development and sale of DermaCompare™, today announced that its proprietary artificial intelligence technology and application for the early diagnosis of melanoma and other skin cancers, was selected as one of four technology start up winners of Merck & Co., Inc. Health Innovation Technology Scouts Program (HITS).
Advertisement
The goal of HITS is to find start up technology companies from around the world that are early in their evolution which Merck can partner with and/or co-create services that complement their core products and future pipeline. After reviewing more than 400 worldwide startup companies in the information technology industry this year, Emerald was selected as one of eight companies to participate in the final judging, which took place on Nov 10, 2016.
Emerald's CEO and President, Adi Zamir and Lior Wayn, presented to Merck's senior executives at the HITS "Be Well Challenge" final, where they were named one of the four winners. As one of the selected winners, Merck has committed to a due diligence process that will determine the potential feasibility of a partnership with the Company.
Adi Zamir CEO of Emerald said "We are proud to have our technology chosen as a winner by a company of Merck's caliber. Their dedication to patients with melanoma is clear; Keytruda is the leading immunotherapy product for melanoma in the world. We believe DermaCompare's ability to identify moles that are suspicious of melanoma could add value to Merck's efforts in the treatment of skin cancer, and look forward to working with them to figure out the best way to implement our technology so that they may help many more people worldwide."
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical technology company that utilizes proprietary military image processing technology and state of the art data analytics to improve the analysis of medical images. Emerald's flagship solution, DermaCompare™, is an FDA Class #1 approved, HIPPA-compliant, skin cancer (melanoma) screening platform that enables physicians to identify and monitor changes in their patients' skin health, specifically the early detection of cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in Mac or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography ("TBP") images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficient than other means of diagnosis
For more information, visit :http://www.dermacompare.com/
About Merck & Co. Inc.
Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through its prescription medicines, vaccines, biologic therapies and animal health products, Merck works with customers and operates in more than 140 countries to deliver innovative health solutions. The company also demonstrates its commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit http://www.merck.com, Twitter, Facebook, YouTube and LinkedIn.
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about Emerald's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Emerald or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Emerald with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Emerald's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Emerald's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Emerald's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Emerald's filings with the SEC. In addition, Emerald operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Emerald does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission on January 20, 2016.
Emerald Medical Applications Contact: Adi Zamir, CEO +972-54-4861247 +972-3-7444505 [email protected]
SOURCE Emerald Medical Applications Corp.
